Oklo to build Groves-2 Forge for on-site isotope processing

A dedicated isotope production plant named Groves-2 Forge will be constructed by advanced nuclear company Oklo. This initiative joins the Nuclear Energy Launch Pad, a federal program managed jointly by the US Department of Energy (DOE) and the National Reactor Innovation Center.

Nuclear Energy Launch Pad selection

The overarching goal of the program is to accelerate the deployment of commercial reactors and domestic fuel cycle technologies. Oklo was selected as one of 12 developers to advance 13 clean-energy projects within this framework.

The new facility will prioritize the creation of life-saving medical isotopes, with lutetium-177 serving as the primary focus. Lutetium-177 acts as the core component in targeted radiopharmaceuticals designed to destroy cancer cells while preserving healthy tissue.

“Many critical isotopes used in cancer treatment, industrial inspection, scientific research, space exploration and national security are currently supplied through aging or foreign facilities,” Oklo stated in a press release.

Consolidating supply chains

Rapid decay rates of medical isotopes mean that extended shipping times can diminish their therapeutic effectiveness before reaching patients. By producing these materials closer to domestic clinics, Oklo intends to protect their potency and eliminate associated supply risks.

Groves-2 Forge addresses this challenge by consolidating the isotope supply chain into a single location. Traditional setups require materials to travel between separate facilities for different processing stages.

The planned site will integrate reactor irradiation directly with specialized “hot-cell” laboratories. This configuration enables technicians to irradiate target materials, separate isotopes, purify the final product, and package it for transport all under one roof.

Building on Texas success

This project leverages Oklo’s recent achievements in Texas. In August, the California-based developer achieved “first criticality” at its low-power Groves Isotope Test Reactor. Criticality defines the point at which a reactor sustains a controlled, continuous nuclear chain reaction.

Oklo transformed an empty greenfield site into full operation in less than 12 months. Constructed under the DOE’s Reactor Pilot Program, it became the first reactor under the scheme to reach criticality on private land. The firm handled engineering, procurement, construction, and startup preparations internally.

Regulatory progress and future licensing

Federal officials highlighted the rapid turnaround as proof that advanced nuclear systems can navigate regulatory channels quickly without compromising safety.

“Oklo’s experience with the Groves Isotope Test Reactor under DOE’s Reactor Pilot Program demonstrates how private developers can advance nuclear projects forward safely and efficiently under DOE authorization,” said Chimi Zacot, Acting Deputy Assistant Secretary for Nuclear Reactors.

Oklo plans to utilize the Groves-2 Forge facility to collect operating data and refine purification methods. This operational experience aims to support the firm in securing formal commercial licenses during its transition to full-scale industrial supply.

“Groves showed how quickly a new reactor could be built and brought to criticality through close collaboration between the private sector and DOE,” concluded Oklo co-founder and chief executive Jacob DeWitte. “Groves-2 Forge will build directly on that foundation by adding the capabilities needed to irradiate target materials and process and prepare valuable isotopes.”